21 Septembre 2021
Stanislas Veillet discusses the preparation for Sarconeos commercialization in the first half of 2021.
biophytis.comCrawled Nov 22, 2026
Stanislas Veillet discusses the preparation for Sarconeos commercialization in the first half of 2021.
Bio101 is an oral small molecule targeting the root cause of muscle loss.
The program aims to preserve muscle mass during weight loss in obesity, which affects over a billion people worldwide.
The page describes sarcopenia as a condition involving progressive loss of skeletal muscle mass and strength, reducing physical performance.
The longevity platform targets aging markers, focusing on cellular and molecular processes linked to aging and associated diseases.
The company explores the therapeutic potential of its drug candidates in aging-related diseases and muscle disorders.
The page explains Biophytis’s mission to make healthy longevity over a century a reality for humanity.
Biophytis Biopharmaceutical (Hong Kong) Group Limited is a joint venture to develop and commercialize BIO101 for sarcopenia in Asian markets.
Biophytis is a biotech company developing innovative therapies to impact longevity, led by its main asset, BIO101, an oral small molecule.
Biophytis develops treatments to slow aging and improve sustainable health, including BIO101.
Biophytis has begun operations for its joint venture in China. The company expands its presence in the Asian market through this strategic partnership, though specific details about the venture’s structure, partners, or immediate activities remain unstated.
Biophytis releases its financial performance for the first half of 2026. The company outlines its strategic priorities and operational focus moving forward.
Biophytis secures €5.3 million in new capital to advance its phase 2 obesity trial. The funding includes €4.75 million in cash and €0.55 million from Hexagon debt roll, with institutional investors participating. Existing shareholders lose preferential subscription rights in this placement.
Biophytis submits an amendment to the Brazilian Health Regulatory Agency (ANVISA) to assess its experimental compound **BIO101** in a **phase 2 OBA clinical study** focused on obesity. The amendment aims to evaluate whether the drug can limit weight regain in participants. The study remains in progress under the existing protocol framework.
Biophytis secures additional funding to bolster its financial stability. The company now projects its cash runway to last through the first quarter of 2027, extending its operational timeline. This move supports ongoing research and development efforts in its therapeutic pipeline.
Biophytis secures regulatory approval from Brazil’s ANVISA to launch its Phase 2 **OBA** clinical trial for obesity. The company also highlights progress in advancing **BIO101**, its drug candidate targeting obesity treatment. The trial marks a key step in evaluating BIO101’s potential in addressing metabolic disorders.